Table 2. Unadjusted and adjusted hazard ratios for HLA class I and II alleles associated with clinical events in HIV-positive individuals (n=4,829) from the START and SMART pooled cohorts who provided consent for genetic analyses.
All associations with a q-value <0.05 in the multivariable model are shown.
| Clinical event (no. of eventsa) | Allele | Participants with predicted HLA, n(% of cohort) | HLA allele carrier status, n(% with predicted HLA) | Events by allele carrier statusb, n(%) | Univariable | Multivariablec | ||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | q-value | ||||||
| AIDS (n=132) | HLA-DQB1*06:04 | 4,671 (96.7) | Non-carriers | 4,452 (95.3) | 108 (2.4) | 1 | 1 | |
| Carriers | 219 (4.7) | 15 (6.8) | 2.75 (1.6–4.7) | 2.63 (1.5–4.6) | 0.041 | |||
| HLA-DRB1*13:02 | 3,800 (78.7) | Non-carriers | 3,410 (89.7) | 79 (2.3) | 1 | 1 | ||
| Carriers | 390 (10.3) | 22 (5.6) | 2.50 (1.6–4.0) | 2.25 (1.4–3.7) | 0.041 | |||
| Bacterial pneumonia (n=167) | HLA-B*15:17 | 3,963 (82.1) | Non-carriers | 3,921 (98.9) | 127 (3.2) | 1 | 1 | |
| Carriers | 42 (1.1) | 7 (16.7) | 5.57 (2.6–11.9) | 4.93 (2.3–10.7) | 0.005 | |||
| HLA-DPB1*15:01 | 4,479 (92.8) | Non-carriers | 4,423 (98.7) | 142 (3.2) | 1 | 1 | ||
| Carriers | 56 (1.3) | 7 (12.5) | 4.08 (1.9–8.7) | 4.33 (2.0–9.3) | 0.015 | |||
| Infection-related cancer (n=45) | HLA-A*69:01 | 4,598 (95.2) | Non-carriers | 4,585 (99.7) | 42 (0.9) | 1 | 1 | |
| Carriers | 13 (0.3) | 2 (15.4) | 19.06 (4.6–78.8) | 15.26 (3.5–66.7) | 0.027 | |||
a
Total number of events in the pooled cohort.
b
The total number of events among allele carriers and non-carriers will vary depending on the number of participants with predicted HLA at each HLA locus.
c
Time to first event adjusted for time-updated log2CD4+ T-cell count, time-updated log10viral load, race, geographical region, sex and age at baseline and stratified by treatment group within trial.
HR: hazard ratio, CI: confidence interval.